Role of transurethral resection in dissemination of cancer of prostate

Levine, E. S.; Cisek, Victor J.; Mulvihill, Michael; Cohen, Elliot L.

doi:10.1016/0090-4295(86)90038-5

Cited by 24 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreno et al [3] detected prostate cancer cells in the peripheral blood circulation in all cases undergoing pTURP, although the clinical relevance of this finding remains unclear. There is a long‐standing debate on the potential negative effect of pTURP on the oncological outcome [4,7–18]. A series of studies analysed the outcome of patients whose cancer was diagnosed either by TURP (incidental) or by biopsy, and who subsequently had external beam radiation [4,7–17].…”

Section: Discussionmentioning

confidence: 99%

Palliative transurethral resection of the prostate: functional outcome and impact on survival

et al. 2006

View full text Add to dashboard Cite

(0.7-5000) ng/mL and the mean Gleason score was 7. The mean ( SD , range) interval between the diagnosis of prostate cancer and pTURP was 1.5 (0.3, 0.5-10.9) years. The indications for pTURP were refractory urinary retention in 30%, severe bladder outlet obstruction with a postvoid residual urine volume of > 100 mL in 43%, and bladder stones, haematuria and hydronephrosis in 9% each. The mean ( SD , range) follow-up after pTURP was 2.6 (0.2, 0.1-7.3) years. The peri-operative mortality ( < 30 days) was 2%, and 22 patients (25%) died during the follow-up. As estimated by Kaplan-Meier analysis, the 1-, 2-and 5-year survival rates were 83%, 70% and 61%, respectively. Patients with prostate cancer in the pTURP specimen had a shorter 3-year survival (52%) than those with a negative histology (89%, P = 0.03). At the last follow-up, 79% of men voided spontaneously and were continent. A repeat pTURP was necessary in 25% of patients, 11% required permanent catheterization and 10% were incontinent. CONCLUSIONDespite greater peri-operative mortality and morbidity than conventional TURP, pTURP is a fairly safe and effective procedure. Although a potential negative impact of pTURP on survival cannot be excluded, the estimated 5-year survival of 61% in this series seems to justify this intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Palliative transurethral resection of the prostate: functional outcome and impact on survival

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Dissemination of cancer cells may occur during TUR, but the effect on the clinical outcome is controversial [30–32]. Our previous report could not find any adverse effects on the prognosis of the studied patients [15, 16].…”

Section: Discussionmentioning

confidence: 99%

Management of Localized Prostate Cancer by Focal Transurethral Resection of Prostate Cancer: An Application of Radical TUR-PCa to Focal Therapy

Morita¹,

Matsuura

2012

Advances in Urology

View full text Add to dashboard Cite

Background. We analyzed radical TUR-PCa against localized prostate cancer. Patients and Methods. Seventy-nine out of 209 patients with prostate cancer in one lobe were studied. Patients' age ranged from 58 to 91 years and preoperative PSA, 0.70 to 17.30 ng/mL. In other 16 additional patients we performed focal TUR-PCa. Patients' age ranged from 51 to 87 years and preoperative PSA, 1.51 to 25.74 ng/mL. Results. PSA failure in radical TUR-PCa was 5.1% during the mean follow-up period of 58.9 months. The actuarial biochemical non-recurrence rate was 98.2% for pT2a and 90.5% for pT2b. Bladder neck contracture occurred in 28 patients (35.4%). In 209 patients, pathological study revealed prostate cancer of the peripheral zone near the neurovascular bundle bilaterally in 25%, unilaterally in 39% and no cancer bilaterally in 35%, suggesting the possibility of focal TUR-PCa. Postoperative PSA of 16 patients treated by focal TUR-PCa was stable between 0.007 and 0.406 ng/mL at 24.2 months' follow-up. No patients suffered from urinary incontinence. Bladder neck contracture developed in only 1 patient and all 5 patients underwent nerve-preserving TUR-PCa did not show erectile dysfunction. Conclusion. Focal TUR-PCa was considered to be a promising option among focal therapies against localized prostate cancer.

show abstract

“…Several studies since then have raised the possibility that palliative TURP contributes to metastatic spread of disease via tumor spillage and hematologic dissemination [6,7]. However, at least one study demonstrated that the association between TURP and disease progression was limited to localized prostate cancer, with minimal risk of disease acceleration in patients presenting with locally advanced disease [8].…”

Section: Palliative Transurethral Resection Of the Prostatementioning

confidence: 99%